{"id":57289,"date":"2026-06-08T20:19:40","date_gmt":"2026-06-08T23:19:40","guid":{"rendered":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/"},"modified":"2026-06-08T20:19:40","modified_gmt":"2026-06-08T23:19:40","slug":"dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral","status":"publish","type":"post","link":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/","title":{"rendered":"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral"},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nDiabetology Limited (Jersey) (<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetology.co.uk%2Fada-poster&amp;esheet=54549179&amp;newsitemid=20260607457696&amp;lan=pt-BR&amp;anchor=https%3A%2F%2Fdiabetology.co.uk%2Fada-poster&amp;index=1&amp;md5=a56016267cb044e9481f65affe61a847\" rel=\"follow\" shape=\"rect\" target=\"_blank\">https:\/\/diabetology.co.uk\/ada-poster<\/a>) 1724-P na 86\u00aa Sess\u00e3o Cient\u00edfica da ADA, em Nova Orleans, relatando os primeiros dados em humanos do Oraglutide\u2122 \u2014 semaglutida oral de libera\u00e7\u00e3o intestinal em pequenas c\u00e1psulas, formulada com a tecnologia propriet\u00e1ria de administra\u00e7\u00e3o Axcess\u2122.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nPRINCIPAIS DESTAQUES<\/p>\n<ul class=\"bwlistdisc\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<li><b>Controle glic\u00eamico por 6 dias:<\/b> Uma \u00fanica dose oral de 4 mg de Oraglutide\u2122 produziu uma queda sustentada na glicose. Medindo 14% no 6\u00ba dia (p=0,046), a maior dura\u00e7\u00e3o apresentada para uma \u00fanica dose oral de GLP-1 em um estudo de teste de toler\u00e2ncia &agrave; glicose intravenosa (IVGTT) em humanos.\n<\/li>\n<li><b>28% increase in insulin secretion:<\/b> Aumento de 28% na secre\u00e7\u00e3o de insulina: Em rela\u00e7\u00e3o ao placebo, a porcentagem da \u00e1rea sob a curva (AUC) da insulina aumentou 12% no dia 0 (p=0,02) e 28% no dia 1 (p=0,025).\n<\/li>\n<li><b>Novo efeito de dep\u00f3sito intestinal:<\/b> Os n\u00edveis sangu\u00edneos de semaglutida foram mais elevados no Dia 1 do que no Dia 0, o que est\u00e1 de acordo com o efeito de dep\u00f3sito associado aos lip\u00eddios na parede intestinal, uma descoberta farmacol\u00f3gica fundamentalmente nova.\n<\/li>\n<li><b>N\u00e3o foram observadas n\u00e1useas ou efeitos colaterais:<\/b> N\u00e3o foram observados eventos adversos em toda a coorte de 8 indiv\u00edduos ao longo de uma semana, o que est\u00e1 de acordo com o direcionamento aos mecanismos aferentes vagais, evitando picos de exposi\u00e7\u00e3o fora do alvo na circula\u00e7\u00e3o externa.\n<\/li>\n<li><b>Dose &gt;6 vezes menor que Rybelsus:<\/b> A biopot\u00eancia pelo menos seis vezes maior que a de Rybelsus (R2) abre caminho para formula\u00e7\u00f5es de Oraglutide\u2122 de baixa dose e longa dura\u00e7\u00e3o, al\u00e9m de formula\u00e7\u00f5es de manuten\u00e7\u00e3o e preven\u00e7\u00e3o de efeito rebote com microdoses de Satietyde\u2122.\n<\/li>\n<li><b>N\u00edveis sangu\u00edneos circulantes<\/b> suficientes para ativar os receptores pancre\u00e1ticos de GLP-1 observados at\u00e9 o 4\u00ba dia.\n<\/li>\n<li><b>Cobertura de patente da plataforma at\u00e9 2044:<\/b> A tecnologia de formula\u00e7\u00e3o Axcess\u2122 licenciada pela Diabetology \u00e9 protegida por patentes e pedidos de patente que se estendem at\u00e9 2044.\n<\/li>\n<\/ul>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA possibilidade de ades\u00e3o ideal ao tratamento com Oraglutide\u2122, gra\u00e7as &agrave; conveni\u00eancia de uma c\u00e1psula oral semanal, segue o regime bem estabelecido de inje\u00e7\u00e3o semanal de GLP-1.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nThe longer action and lower side effect profile emerges from the considerably lower A a\u00e7\u00e3o prolongada e o perfil de efeitos colaterais mais baixo decorrem da dosagem oral consideravelmente menor e da via de administra\u00e7\u00e3o mais fisiol\u00f3gica atrav\u00e9s da parede intestinal. \u00c9 nesse local que a maior parte do GLP-1 \u00e9 produzida naturalmente e onde existem receptores do nervo vago para desencadear a saciedade via c\u00e9rebro. Essas vantagens podem reduzir significativamente os custos gerais da terapia, diminuir as taxas de abandono e os efeitos colaterais, al\u00e9m de abrir a possibilidade de microdosagem de Satietyde\u2122 para reduzir os efeitos rebote ap\u00f3s tratamentos para obesidade.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><span id=\"mmgallerylink-phrase\">Ver a vers\u00e3o original em businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260607457696\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260607457696\/pt\/<\/a><\/span><\/p>\n<p><b>Contato:<\/b><\/p>\n<p>\nContato: Diabetology Limited\n<\/p>\n<p>P\u00e1gina Web: <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetology.co.uk&amp;esheet=54549179&amp;newsitemid=20260607457696&amp;lan=pt-BR&amp;anchor=https%3A%2F%2Fdiabetology.co.uk&amp;index=2&amp;md5=8a926339d8ff131a83bb81066f93c7d7\" rel=\"follow\" shape=\"rect\">https:\/\/diabetology.co.uk<br \/>\n<\/a><\/p>\n<p>E-mail: <a href=\"mailto:media@diabetology.co.uk\" rel=\"follow\" shape=\"rect\">media@diabetology.co.uk<br \/>\n<\/a><\/p>\n<p>Dr. Roger New, Cofundador e Diretor Cient\u00edfico (CSO) &#8211; Reino Unido: +44 (0) 7818 068012\n<\/p>\n<p>Glen Travers, Cofundador e CEO: +44 (0) 7785308176\n<\/p>\n<p>Gary Walton, Diretor Financeiro (CFO) &#8211; Oceania: +61 (0) 419425205\n<\/p>\n<p>Sukumar R \u00cdndia: +91 (0) 7738385489<\/p>\n<p><strong>Fonte: <\/strong><a href='http:\/\/www.businesswire.com\/portal\/site\/home\/' target='_blank'>BUSINESS WIRE<\/a><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/332236?partnerId=3197' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diabetology Limited (Jersey) (https:\/\/diabetology.co.uk\/ada-poster) 1724-P na 86\u00aa Sess\u00e3o Cient\u00edfica da ADA, em Nova Orleans, relatando os primeiros dados em humanos do Oraglutide\u2122 \u2014 semaglutida oral de libera\u00e7\u00e3o intestinal em pequenas c\u00e1psulas, formulada com a tecnologia propriet\u00e1ria de administra\u00e7\u00e3o Axcess\u2122. PRINCIPAIS DESTAQUES Controle glic\u00eamico por 6 dias: Uma \u00fanica dose oral de 4 mg de Oraglutide\u2122 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-57289","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"og:description\" content=\"Diabetology Limited (Jersey) (https:\/\/diabetology.co.uk\/ada-poster) 1724-P na 86\u00aa Sess\u00e3o Cient\u00edfica da ADA, em Nova Orleans, relatando os primeiros dados em humanos do Oraglutide\u2122 \u2014 semaglutida oral de libera\u00e7\u00e3o intestinal em pequenas c\u00e1psulas, formulada com a tecnologia propriet\u00e1ria de administra\u00e7\u00e3o Axcess\u2122. PRINCIPAIS DESTAQUES Controle glic\u00eamico por 6 dias: Uma \u00fanica dose oral de 4 mg de Oraglutide\u2122 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/\" \/>\n<meta property=\"og:site_name\" content=\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T23:19:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"headline\":\"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral\",\"datePublished\":\"2026-06-08T23:19:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/\"},\"wordCount\":578,\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp\",\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/\",\"name\":\"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp\",\"datePublished\":\"2026-06-08T23:19:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\",\"name\":\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"description\":\"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/author\\\/dino\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/","og_locale":"pt_BR","og_type":"article","og_title":"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","og_description":"Diabetology Limited (Jersey) (https:\/\/diabetology.co.uk\/ada-poster) 1724-P na 86\u00aa Sess\u00e3o Cient\u00edfica da ADA, em Nova Orleans, relatando os primeiros dados em humanos do Oraglutide\u2122 \u2014 semaglutida oral de libera\u00e7\u00e3o intestinal em pequenas c\u00e1psulas, formulada com a tecnologia propriet\u00e1ria de administra\u00e7\u00e3o Axcess\u2122. PRINCIPAIS DESTAQUES Controle glic\u00eamico por 6 dias: Uma \u00fanica dose oral de 4 mg de Oraglutide\u2122 [&hellip;]","og_url":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/","og_site_name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","article_published_time":"2026-06-08T23:19:40+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"DINO","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#article","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/"},"author":{"name":"DINO","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"headline":"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral","datePublished":"2026-06-08T23:19:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/"},"wordCount":578,"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp","articleSection":["Not\u00edcias Corporativas"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/","url":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/","name":"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#primaryimage"},"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp","datePublished":"2026-06-08T23:19:40+00:00","author":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"breadcrumb":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260607457696r1&amp;sid=brdno&amp;distro=ftp"},{"@type":"BreadcrumbList","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/dados-clinicos-inovadores-da-diabetology-com-oraglutide-glp-1-oral\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ocanal.com\/noticias\/corporativas\/"},{"@type":"ListItem","position":2,"name":"Dados cl\u00ednicos inovadores da Diabetology com Oraglutide\u2122, GLP-1 oral"}]},{"@type":"WebSite","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website","url":"https:\/\/ocanal.com\/noticias\/corporativas\/","name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","description":"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocanal.com\/noticias\/corporativas\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff","name":"DINO","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/ocanal.com\/noticias\/corporativas\/author\/dino\/"}]}},"_links":{"self":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/57289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/comments?post=57289"}],"version-history":[{"count":0,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/57289\/revisions"}],"wp:attachment":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/media?parent=57289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/categories?post=57289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/tags?post=57289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}